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The etiologic agent of Chagas Disease is the Trypanosoma cruzi, transmitted through blood-sucking insect vectors of the
Triatominae subfamily, representing one of the most serious public health concerns in Latin America. There are geographic
variations in the prevalence of clinical forms and morbidity of Chagas disease, likely due to genetic variation of the T. cruzi and
the host genetic and environmental features. Increasing evidence has supported that inﬂammatory cytokines and chemokines
are responsible for the generation of the inﬂammatory inﬁltrate and tissue damage. Moreover, genetic polymorphisms, protein
expression levels, and genomic imbalances are associated with disease progression. This paper discusses these key aspects. Large
surveys were carried out in Brazil and served as baseline for deﬁnition of the control measures adopted. However, Chagas disease
is still active, and aspects such as host-parasite interactions, genetic mechanisms of cellular interaction, genetic variability, and
tropism need further investigations in the attempt to eradicate the disease.
1.ChagasDisease
1.1. Epidemiology and Clinical Outcomes. Chagas disease,
also called American trypanosomiasis, remains an epidemi-
ologic challenge more than one hundred years after its
discovery by Carlos Chagas [1]. It is estimated that 12–14
million people are infected with Trypanosoma cruzi in Latin
America where the disease is endemic, and 75–90 million
are exposed to infection [1, 2]. Less frequently, infection
occurs through blood transfusion, vertical transmission
(from infected mother to child), or organ donation [3].
In 2008, it was estimated that more than 10 thousand
people were killed by Chagas disease [3]. In Brazil, the infec-
tion has already aﬄicted about 2.5 million individuals [4]
despite the success of control measures responsible of elimi-
nation of domestic and peridomestic colonies of vector and
monitoring of blood banks, which reduced incidence by
approximately 70% in the Southern Cone countries. Due
to the intense population migration and mobility, Chagas
disease has spread in North America and Europe and is now
global [5, 6].
Chagas disease is characterized by a wide spectrum of
clinical outcomes, ranging from absence of symptoms to
severe disease. Clinical course includes acute and chronic
phases, separated by an indeﬁnite period when patients are
relatively asymptomatic. The acute phase is usually sub-
clinical with deep parasitemia. In the indeterminate phase,
patients have positive serologic and/or parasitological tests
butareasymptomaticwithoutradiographicorelectrocardio-
graphic manifestations of infection [7]. Among the chron-
ically infected individuals, 25 to 30% develop severe heart
disorders [8, 9]. Sixty to 70% of them remain asymptomatic
or develop mega syndromes of the esophagus or colon [10].
In these digestive forms, intestinal dilation and muscular2 Journal of Tropical Medicine
hypertrophy of the esophagus or colon are observed in
advanced stages of disease, named megaesophagus and
megacolon, respectively [11, 12].
The economic impact of Chagas disease is signiﬁcant
and extrapolates the high social cost attributable to chronic
patients. Many people at productive age die prematurely,
since the available therapeutic drugs only kill the extracel-
lular parasites, and there is not an eﬀective treatment for the
disease. It is important to highlight that the damage caused
bytheparasiteisirreversible,leavingconsequencesthatoften
make it impossible for the patients to perform their daily
functions [13–17].
1.2. Vector and Parasite. The etiologic agent of Chagas
Disease is the ﬂagellate protozoan Trypanosoma cruzi,w h i c h
is mainly transmitted from person to person through
blood-sucking insect vectors of the Triatominae subfamily,
representing one of the most serious public health concerns
in South America [18].
1.2.1. Triatominae Vectors. The insect vector of T. cruzi is
dispersed throughout Latin America and in Brazil is often
called “kissing bug” [10]. The potential vectors encompass
more than 144 species of Triatominae insects from the Redu-
viidae family, some of which are epidemiologically more
signiﬁcant such as Triatoma infestans, Triatoma brasiliensis,
Triatoma dimidiata, Rhodnius prolixus, Triatoma pseudomac-
ulata, Triatoma sordida, and Panstrongylus megistus; Figure 1
[15, 19]. The Triatoma infestans is an allochthonous, highly
anthropophilic species with the highest rates of infection. It
was introduced in S˜ ao Paulo state from the south of Brazil
probably during the 18th century, when there was massive
displacement of the agricultural frontier towards the west in
search of virgin land for coﬀee plantation [15].
Currently, the main method of vector control is to spray
houseswithresidualinsecticides. However, theoccurrenceof
T. infestans populations resistant to pyrethroid compounds
in the north of Argentina and Bolivia requires the alternative
use of organophosphate insecticides. Unfortunately, these
insecticides, although eﬀective, are very toxic and less
accepted by the community due to their unpleasant odor
[6, 20, 21].
Since T. infestans genome has not yet been studied,
sequencing of ESTs (expressed sequence tags) is one of the
most powerful tools for eﬃciently identifying large numbers
of expressed genes in this insect vector. A total of 826
ESTs were generated, resulting in an increase of 47% in
the number of ESTs available for T. infestans. These ESTs
were assembled in 471 unique sequences, 151 of which
represent 136 new genes for the Reduviidae family. Among
the putative new genes for this family, an interesting subset
of genes involved in development and reproduction, which
constitutes potential targets for insecticide development, was
identiﬁed and described [6].
1.2.2. Trypanosoma cruzi. Trypanosoma cruzi is a ﬂagellate
protozoan of the Kinetoplastida order and Trypanoso-
matidae family. The parasite’s life cycle alternates between
vertebrates and insects, with diﬀerent major principal
developmental stages in each host. In the hematophagous
vector, the infective replicative epimastigotes (stage with
kinetoplast and ﬂagellar pouch in the anterior position of
the nucleus), the metacyclic trypomastigotes (kinetoplast in
the extremity posterior to the nucleus), and the replicative
intracellular amastigotes predominate (rounded form with
short inconspicuous ﬂagellum); in the mammalian host the
bloodstream trypomastigotes predominate [7]( Figure 2).
Naturally acquired T. cruzi infections are initiated in the
dermal layers or conjunctival mucosa by infective metacyclic
trypomastigote forms that are transmitted by an infected
hematophagous triatomine vector [22] and are thereby
transformed into amastigotes with the capacity to multiply
by simple binary division. Next, they diﬀerentiate into
trypomastigotes that are released by the host cell into the
interstitium and reach the bloodstream and are thus able to
invade cells from any tissue to produce a new cycle or be
destroyed by host immune mechanisms [7].
2. Clonal HistotropicModel of ChagasDisease
There are geographic variations in the prevalence of clinical
forms and morbidity of Chagas disease, likely due to both
the genetic variation of the T. cruzi and the genetic and
environmental features of the host [23, 24]. The molecular
interaction between the cell surface of the T. cruzi clones
and the host tissue would be the most likely basis for this
tropism.Duetobiologicalpolymorphism,diﬀerentclonesin
a lineage can present tropism for diﬀerent tissues, becoming
a determinant factor for the disease clinical course due to
the clonal repertoire of the infecting lineage and its speciﬁc
tropisms. This scenario is at the center of what is referred to
as the “clonal histotropic model” of Chagas disease [23].
During the Chagas disease acute phase, parasites are
present in diﬀerent organs, but in the chronic phase, they
damage speciﬁc organs, manifesting genetic heterogeneity
among isolates and stocks that may explain the degree of
tropism for diﬀerent organs [33]. The invasion of non-
phagocytic host cells by T. cruzi depends on parasite surface
glycoproteins, and the ability of metacyclic trypomastigotes
infectivity varies between diﬀerent populations of the par-
asite. These glycoproteins have diﬀerential activity in the
signaling of Ca2+ ions [34].
It has been shown that T. cruzi invading mammalian
cells binds to the TrkA receptor, the receptor tyrosine
kinase widely expressed in the mammalian nervous sys-
tem, activating TrkA-dependent survival mechanisms, and
facilitating its adherence, invasion, and survival [35]. This
binding is mediated by the parasite-derived neurotrophic
factor (PDNF), a transsialidase located on the surface of the
parasite. PDNF in the cytosol of the host cell apparently
activates Akt signaling, leading to a suppression of apoptosis
[36].Furthermore,T.cruzitranssialidasebindstoendothelial
cells, triggering activation of NF-kB and leading to protec-
tion against apoptosis caused by growth factor deprivation
[37].
Murine microarrays studies identiﬁed 353 murine genes
that were diﬀerentially expressed during the early stages ofJournal of Tropical Medicine 3
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Figure 1: Some of Triatominae insects from the Reduviidae family, which are epidemiologically more signiﬁcant as potential vectors: (a)
Triatoma sordida;( b )Triatoma infestans;( c )Triatoma pseudomaculata;( d )Panstrongylus megistus;( e )Triatoma brasiliensis;( f )Triatoma
dimidiata;( g )Rhodnius prolixus.
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Figure 2: Developmental stages of Trypanosoma cruzi. (a) Amastigote, the nonﬂagellate intracellular morphologic stage; (b) epimastigote,
long spindle-shaped hemoﬂagellate morphologic form equipped with a free ﬂagellum and an undulating membrane that extends one half
of the body length. It is found in the vectors responsible for transmitting the Trypanosoma species; (c) promastigote, characterized by a free
anterior ﬂagellum and the kinetoplast at the anterior end of the body; (d) trypomastigote, leaf-like form with an undulating membrane and
often a free ﬂagellum; (e) choanomastigote, barleycorn shaped with a collar-like process where the ﬂagella emerges. Intracellular stage inside
the invertebrate host; (f) opisthomastigote, no undulating membrane. Found in the invertebrate host only. (1) Nucleus, (2) kinetoplast, (3)
basal body, (4) ﬂagellar pocket (5) ﬂagellum, (6) undulating membrane, (7) mitochondrion, and (8) subpellicular microtubules.
invasion and infection by T. cruzi of primary murine car-
diomyocytes. Genes associated with the immune response,
inﬂammation, cytoskeleton organization, cell-cell and cell-
matrix interactions, apoptosis, cell cycle, and oxidative stress
are among those aﬀected during the infection [38].
T. cruzi is divided into six discrete typing units (DTU):
TcI,TcIIa,TcIIb, TcIIc,TcIId, andTcIIe[39–42]. Geograph-
ical and epidemiological studies showed that the distribution
of TcI and TcII varies geographically. TcI is prevalent in
the northern region of Brazil, Central and North America
[43, 44], while TcII is found predominantly in the Southern
cone countries of Latin America [45]. In Bolivia, the TcIId
was found to be the most common [45].
The T. cruzi kinetoplast minicircle DNA (kDNA) appears
tobeessentialforthestudyofT.cruzigeneticvariabilityfrom
diﬀerent tissues. PCR (polymerase chain reaction) detection
of T. cruzi DNA was performed randomly (i.e., without
previouslydetermining inﬂammatory foci) in the esophageal
tissue fragments collected from 52 Chagas disease patients.
The T. cruzi kDNA 330-bp product was detected in 69.2%
of esophageal samples, of which 25% were conﬁrmed only
after hybridization. The PCR of blood ampliﬁed the 330-
bp fragment corresponding to T. cruzi k-DNA in 90.4% of
subjects, of which 83% were detected before hybridization
of the ampliﬁed products. It was not possible to show a
direct relationship between positive tissue and positive blood
parasitism because of 40 patients who had tissue parasitism,
92.5% had positive blood PCR, and T. cruzi was also
detected in the blood of 83.3% of the subjects with negative
tissue parasitism. A correlation between the frequency and
intensity of the inﬂammatory process in tissues and the
presence of T. cruzi could be observed, especially in cases of
advanced megaesophagus [46].
Years after, a molecular characterization of parasites eval-
uated the polymorphisms of the 3 region of the 24S rRNA
gene and the variability of kDNA minicircles of T. cruzi
populations by low-stringency single speciﬁc primer LSSP-
PCR and data provided a strong correlation between T. cruzi
II and human infection in an endemic in Southeast Brazil
area. However, a high degree of variability was observed
within T. cruzi II, as demonstrated by intense kDNA
polymorphism among all clinical forms and also within each
ofthem,irrespectiveoftheintensityofpathologicalprocesses
[47].
T. cruzi lineages and (sub)lineages were typiﬁed in
megacolon samples from 18 Bolivian patients using kDNA4 Journal of Tropical Medicine
probes speciﬁc of lineage TcI, TcIIb, TcIId, and TcIIe. The
majority of the samples (16/18) were (sub)lineage TcIId
positive.However,twosampleswerepositivefor(sub)lineage
TcIIb.Twosyntheticprobesdiscriminatedvariantsoflineage
TcIId. Proportion of TcIId variants encountered were 6/16,
6/16, and 4/16, similar to the distribution of Chagasic
populations in Bolivia. The data suggest that there is no
preferential tropism of one particular lineage or variant of
T. cruzi II in megacolon pathology [48].
T. cruzi kDNA minicircle signatures were evaluated
using LSSP-PCR technique in both peripheral blood and
esophageal mucosa from Brazilian chronic chagasic patients,
with or without megaesophagus, alone or in combination
with cardiopathy and megacolon. The study failed to identify
a uniform pattern of shared bands between blood and
esophageal mucosa samples from individuals with a speciﬁc
or mixed clinical forms, which suggested occurrence of
multiple T. cruzi infections with diﬀerential tissue tropism.
The study evidenced an intense intraspeciﬁc variability in
the hypervariable regions of the T. cruzi kDNA, which
has made it impossible to correlate the genetic proﬁle of
these hypervariable regions with the Chagas disease clinical
manifestations [49].
A study in peripheral blood of 306 Bolivian chronic
Chagas disease patients (81 with cardiopathy/150 without
cardiopathy; 100 with megacolon/144 without megacolon;
164 with cardiopathy or megacolon/73 indeterminate/17
cases with both cardiopathy and megacolon) successfully
ampliﬁed the kDNA of T. cruzi from 196 samples (64.1%).
Of those, 104 (53.3%) were TcIId, 4 (2.0%) were TcI, 7
(3.6%) were TcIIb, 1 (0.5%) was TcIIe, 26 (13.3%) were
TcI/IId, 1 (0.5%) was TcI/IIb/IId, 2 (1.0%) were TcIIb/d,
and 51 (25.9%) were unidentiﬁed. Of the 104 Tc IId
samples, three diﬀerent kDNA hypervariable region patterns
were detected, Mn (49.6%), TPK-like (48.9%), and Bug-like
(1.5%). However, none of the identiﬁed lineages or sublin-
eages was signiﬁcantly associated with any particular clinical
manifestations in the chronic Chagas disease patients [50].
Then, the infection of individual Chagas disease patients
may be produced by genetically diverse mixed parasite
populations, so it is diﬃcult to establish a relationship
between sublineages of parasite and clinical manifestation of
Chagas disease.
3. GeneticStudiesof Chagas DiseasePatients
3.1. Cardiomyopathies. The pathogenesis of chronic chagasic
cardiomyopathy (CCC) is not well understood. Since studies
showed that myocarditis is more frequent during advanced
stages of the disease and the prognosis of CCC is worse than
that of other dilated cardiomyopathies of noninﬂammatory
etiology, it seems that the inﬂammatory inﬁltrate plays
a major role in myocardial damage [51, 52]. In the last
decade, increasing evidence has supported that inﬂam-
matory cytokines and chemokines are responsible for the
generation of the inﬂammatory inﬁltrate and tissue damage.
CCC patients have an increased peripheral production of
the inﬂammatory Th1, cytokines IFN-γ,a n dT N F - α when
compared to patients with the asymptomatic/indeterminate
form. Moreover, Th1-T cells are the main producers of
IFN-γ and TNF-α and are frequently found in CCC
myocardial inﬂammatory inﬁltrate. Furthermore, genetic
polymorphisms of cytokine, chemokine, and innate immune
response genes have been associated with disease progression
[53].
CCC exhibits high levels of circulating procytokines,
and lymphocytic inﬁltrates presenting cytokines (TNF-α
and IFN-γ) are detectable in specimens of cardiac surgical
biopsy and tissue [27]. Thus, diﬀerent polymorphisms in
genes of pro- and anti-inﬂammatory cytokines and others
genesinvolved inhostimmune response havebeenevaluated
in CCC patients (Table 1). Due to the role of TNF-α in
the progression of heart failure and to increased levels of
plasma and cardiac tissue observed in CCC, Drigo et al.
[25] investigated the microsatellite polymorphism (TNFa2)
and the promoter polymorphism of TNF-308 (TNF2)i n4 2
patients with severe ventricular dysfunction, according to
the presence of the allele TNF2 promoter or microsatellite
TNFa2-308. The authors observed that positive patients for
the alleles TNF2 or TNFa2 exhibited a signiﬁcantly shorter
survival time compared with those carrying other alleles,
thus suggesting that the TNF genotype can be targeted in
therapeutic interventions. However, no association between
TNF polymorphism and the severity of the injury was
detected [26] when comparing CCC and asymptomatic
Chagas disease patients (ASY).
BAT1 (HLA-B-associated transcript 1), a gene with anti-
inﬂammatory activity, and LTA (lymphotoxin alpha), a pro-
inﬂammatory cytokines member of the TNF family have
been associated with coronary artery disease and myocardial
infarction [27, 28]. PCR-RFLP (polymerase chain reaction-
restriction fragment length polymorphism) studies inves-
tigated variants in the promoter region of BAT1 in posi-
tions −22C/G and −348C/T [27]a n dLTA in positions
−80A3C and −252A3G [28] in CCC and ASY patients.
Homozygous BTA-22CC constituted 16% of CCC but only
4% of ASY. Similar results were observed for allele −348C,
suggesting that BAT1 variants, previously associated with
reduced expression of HLA-B-1, are predictive of CCC
evolution. These variants may be less eﬃcient in down-
regulation of inﬂammatory response and may contribute to
increasedproductionofpro-inﬂammatorycytokinesinCCC
[27]. The homozygous alleles LTA-80C and LTA-252G were
signiﬁcantly more frequent in CCC than in ASY (47% versus
33% and 16% versus 8%, resp.). The LTA haplotype −80C–
252G was also associated with susceptibility to CCC. The
authors concluded that the study of these genetic variations
may help identify Chagas disease patients at increased risk of
developing CCC [28].
Because pro-inﬂammatory cytokines play an important
role in CCC, probably SNPs (Single Nucleotide Polymor-
phisms) in the genes that encode proteins in the TLR
(Toll-like receptor) pathway could explain diﬀerential sus-
ceptibility to CCC among T. cruzi-infected individuals. T.
cruzi-infected individuals who are heterozygous for the
MAL/TIRAP S180L variant that leads to a decrease in
signal transduction upon ligation of TLR2 or TLR4 to theirJournal of Tropical Medicine 5
Table 1: Genetic polymorphisms in Chagas disease cardiomyopathy.
Genes SNP Eﬀect
Association to cardiomyopathy
References
Patients Results
TNFα
Pro-inﬂammatory
cytokines [25, 26]
−308G/A
(TNF2)
TNFa2
High TNF-a production 42 CCC
Allele TNF2 or microsatellite TNFa2
associated with worse prognosis
Shorter survival time compared with those
carrying other alleles
[25]
166 CCC
80 ASY
No signiﬁcant diﬀerences between CCC and
ASY patients
Lack of association of TNF polymorphisms
with CCC development or to progression
cardiomyopthy
[26]
BAT1
−22C/G
−348C/T
Anti-inﬂammatory activity
associated with reduced
expression of HLA-B-1
154 CCC
76 ASY
Homozygous −22CC and −348CC more
frequent in CCC than in ASY
Both variants are predictive of CCC evolution
[27]
LTA +80A/C
+252A/G
Pro-inﬂammatory
cytokines
169 CCC
76 ASY
Homozygous +80CC and +252GG more
frequent in CCC than in ASY
Haplotype +80C +252G associated to CCC
susceptibility
[28]
TLR
TLR1
TLR2
TLR4
TLR5
TLR9
Pathogen recognition
receptors
Component of innate
immunity
169 CCC
76 ASY
TLR polymorphisms did not show major risk
factors for the development of CCC [29]
MAL/TIRAP Encodes an adaptor protein
for TLR
169 CCC
76 ASY
Heterozygous MAL/TIRAP S180L associated
with lower risk of developing CCC [29]
TGFβ1
−988 C/A
−800 G/A
−509 C/T
10 T/C
263 C/T
Multifunctional cytokine
172 CCC
175 ASY
279 health
control patients
−988 C/A and 263 C/T were not detected
−800A was uncommon, and −509 C/T was
not associated with Chagas disease
Allele C and the genotype C/C at codon 10
were associated with Chagas disease patients
Allele C may be a risk factor for genetic
susceptibility to Chagas disease patients
[30]
MASP2 Six SNP Involved in the
complement system
208 Chagas
disease
300 health
control patients
MASP2 ∗CD genotypes were associated risk
of CCC [31]
IL-1B
IL-1B-511
IL-1F10.3
IL-1RN.4
IL-1RN 6/1
IL-1RN 6/2
Pro-inﬂammatory
cytokines
Receptor antagonist
58 CCC
28 ASY
50 IDC
Ca l l e l eo rC Cg e n o t y p eo ft h eIL-1RN.4 was
increased in CCC
when compared with IDC and health control
patients, evidencing association between this
polymorphisms and CCC development
[32]
ASY: asymptomatic patients; CCC: chronic Chagasic cardiomyopathy patients; IDC: idiopathic dilated cardiomyopathy patients.
respective ligand may have a lower risk of developing CCC
[29].
Among the cytokines, TGFβ1 (transforming growth fac-
tor beta multifunctional 1) is essential for the establishment
and pathogenesis of T. cruzi infection. Several SNPs in this
gene able to aﬀect cytokine production have been described,
and ﬁve of them with functional signiﬁcance (−988 C/A;
−800 G/A; −509 C/T, 10 T/C; 263 C/T) were investigated
[30]. The distribution of alleles 10T and 10C showed a
signiﬁcant diﬀerence between patients (CCC and ASY) and
healthy controls. Additionally, the high frequency of 10 C/C
genotype was increased in Chagas disease patients. These
data suggest that genetic polymorphisms in codon 10 of
TGFβ1 may be involved in susceptibility to infection with T.
cruzi in South American patients [30].
Mannose-binding lectin (MBL) initiates complement
on T. cruzi through the MBL-associated serine protease 2
(MASP2). Chronic Chagas disease patients were haplotyped
[208: including 81 indeterminate and 123 symptomatic
(76 with cardiac, 19 with digestive, and 28 with cardio-
digestive forms)] for six MASP2 polymorphisms using PCR
with sequence-speciﬁc primers and compared with 300
healthy individuals from Southern Brazil. The g.1961795C,
p.371D diplotype occurred at a higher frequency among6 Journal of Tropical Medicine
symptomatic patients, compared with the indeterminate
group, as well as genotypes with Chagas disease, but not
with the g.1945560A in the promoter in cardiac patients.
CD haplotypes linked to the p.P126L and p.V377A variants
were associated with reduced MASP-2 levels but not reduced
MBL/MASP-2/C4 complexes. The authors concluded that
MASP2∗CD genotypes, most of them generating low MASP-
2 levels, are associated with high risk of chagasic cardiomy-
opathy [31].
Though it is known that the immune system exerts some
inﬂuence on the resistance against T. cruzi infection, its
precise role in this process is not well understood. Some IL-
1B alleles and haplotypes have been associated with suscepti-
bility to inﬂammatory, autoimmune, and infectious diseases.
An investigation of polymorphism (IL-1B-511, IL-1F10.3
IL-1RN.4, IL-1RN 6/1, and IL-1RN 6/2) was conducted in
86 T. cruzi seropositive patients (58 CCC and 28 ASY), 50
seronegativepatientswithidiopathicdilatedcardiomyopathy
(IDC) and 109 healthy individuals using RT-PCR allelic
discrimination technology. Infected patients presented an
increased frequency of the CC genotype of the IL-1RN.4
polymorphism when compared to IDC. The C allele or CC
genotype of this polymorphism was found increased in CCC
when compared with IDC and with controls, suggesting an
evident association between the IL1RN.4 polymorphism, T.
cruzi infection, and CCC development [32].
These studies evidence the association of various poly-
morphisms in genes of immune response and susceptibility
to chagasic cardiopathy, so suggesting that host genetic
factors may play a role in the underlying mechanisms of
disease pathogenesis.
3.2. Digestive Tract Alterations. The digestive manifesta-
tions of Chagas disease mainly involve megaesophagus and
megacolon [3]. The abnormalities of the autonomic enteric
nervous system seem to be an essential element in the
pathogenesis of chagasic megavisceras. These abnormalities
include degeneration and reduction in the number of
myenteric plexus that coordinates the motor activity of
diﬀerent segments from the esophagus to the rectum [54].
These lesions occur throughout the digestive tract, but the
esophagus and distal portion of the colon are the parts most
aﬀected because of the physiology of these segments [55]
Furthermore, both regions have a sphincter at their end that
must relax by a reﬂex mechanism.
Van Voorhis and Eisen [56] characterized one cross-
reactive antigen (Fl-160), which correspond to an antibody
found on the surface of the trypanosome, overlying the ﬂag-
ellum. This antibody cross-reacts with a 48-kD mammalian
nervous tissue protein found in sciatic nerve, brain, and
myenteric plexi of gut. The myenteric plexi are destroyed
by inﬂammatory inﬁltrates in Chagas disease, leading to the
characteristic megaesophagus and megacolon.
Comparison of the cellular immune response in patients
with the digestive and indeterminate forms of Chagas disease
on the basis of lymphocyte proliferation and cytokine
production after antigen or mitogen stimulation showed
no signiﬁcant diﬀerences between patient groups on pro-
liferative response or on TNF-α and interleukin (IL)-10
levels, although IL-10 achieves higher levels than TNF-α
after T. cruzi antigen stimulation. IFN-γ basal production
was signiﬁcantly higher in the digestive form and IL-4
was signiﬁcantly higher in patients with megaesophagus
when compared with patients with megacolon. These results
indicated that patients with the digestive form of Chagas
disease do not suﬀer immune suppression and that the
cytokine balance favors a strong inﬂammatory reaction in
patients with the digestive form, which may contribute to
lesions of the enteric nervous system [57].
3.2.1. Megaesophagus. Chagasic megaesophagus is conse-
quence of achalasia characterized by the destruction or lack
of intramural nerve plexus, which determines the absence
of peristalsis and lack of openness of the lower esophageal
sphincter in response to swallowing. In consequence, food
retention or esophageal stasis occurs, leading to the appear-
ance of chronic esophagitis, acanthosis, paraceratose, and
leukoplakia, possibly precancerous lesions [57].
Megaesophagus patients have high variability in
esophageal microbiota, which consists primarily of Gram-
positive anaerobic bacteria, correlated with the degree
of esophageal dilatation [58, 59]. One of the severe late
consequences of megaesophagus is the increased risk (3%
to 8%) of developing esophageal squamous cell carcinoma
(ESCC) [59–61]. Also, ESCC develops in megaesophaus
patients at a younger age than in those without this disease
[62]. Tumor development is likely related to the prolonged
contact of food with the mucosa due to esophageal stasis,
increased bacterial growth, and chemical irritation, which
results in chronic esophagitis [63].
Idiopathic achalasia and megaesophaus patients, with or
without esophageal carcinoma, described changes in expres-
sion of proteins such as p53, p16, and MIB (mindbomb
homolog)[63–68],chromosomalaneuploidies[59,69],gene
deletions in signiﬁcant (TP53) [69]o rm a r gi n a ll e v e l s( TP63,
FHIT, PIK3CA, EGFR, CDKN2A,a n dYES)[ 70], and gene
copy number gain (PIK3CA, TP63, FGFR1, MYC, CDNK2A,
and NCOA3) mainly associated with dilation grades III
a n dI V[ 70]. A strong immunoreactivity of p53 protein
was found in patients with idiopathic and megaesophaus,
and two of four cases analyzed showed mutations in TP53
codons 238 and 146 of exons 7 and 5, respectively [63]. The
authors suggested that changes in TP53 in megaesophagus
epithelium might be a useful biomarker for identifying
individuals with high risk of carcinoma development. In
otherstudies,thefrequencyofp53proteinimmunoreactivity
increased signiﬁcantly when compared to patients with
normal esophageal mucosa and achalasia [65, 66]. Thus,
these studies suggest that the cell cycle may be altered due
to persistent inﬂammation of mucosa cells, which may arise
during dysplasia-carcinoma sequence.
DNA aneuploidy identiﬁed by image cytometry in
esophageal specimens of patients with megaesophaus was
detectedin27%of15patients;similarchromosomalchanges
also were found in biopsies of megaesophagus, peritumoral
tissue, and the center of the tumor of patients with ESCC
[59], suggesting that the study of precancerous lesions
represents a valuable tool for early diagnosis of esophagealJournal of Tropical Medicine 7
carcinoma.ChromosomalaneuploidiesanddeletionofTP53
werealsodetectedin54%of40megaesophauswithoutESCC
[69]. However, this study has not found mutations in the
genes TP53, CDKN2A,a n dFHIT, which suggested that these
events are not common in this lesion [71].
Immunohistochemical studies showed a progressive
increase of p53 protein expression in megaesophaus (26.1%)
when compared to normal mucosa (7.7%). Also, immuno-
histochemical stain for p16 and Fhit proteins showed focal
and/or diﬀuse distribution on the basal lamina on the
tissue surface for both proteins [68]. However, there is no
evidenceofalterationsincellkineticsinmegaesophaus,since
cell proliferation indexes evaluated by Ki67 antigen, and
apoptosis by CPP32 antibody was similar to normal mucosa
[72]. These studies have shown that p53 overexpression is
involved in the initial steps of esophageal carcinogenesis,
supporting further evaluation of this marker in precursor
lesions [68].
Despite the scarceness of genetic studies in megae-
sophaus, the available data supports occurrence of genetic
changes associated with regulation of the cell cycle control,
similarly to esophageal carcinoma, thus indicating that these
alterations can be involved in the progression of esophageal
carcinogenesis from precursor lesions.
3.2.2. Megacolon. Chagasic megacolon is the large intestine
dilation and elongation, mainly due to changes in the viscera
intrinsic innervation, with consequent morphological and
functional disorders [73]. The megacolon, a complication of
Chagasdiseaseisrelativelycommonandhasbeenconsidered
the most common surgical disease of the colon [73]. It
is diﬃcult to detect natural megacolon, perhaps because
of its slower growth rate, milder symptoms, and tendency
to manifest later in life, or perhaps due to the fact that
the patient supports better symptoms of constipation than
dysphagia. However, it is estimated that 10 to 12% of Chagas
disease cases (around 30,000 per year) develop megacolon
[3].
Megacolon is slightly predominant in men, between 20
and 60 years of age, and peaking around 40–50 years. The
disease is mostly acquired in rural areas due to contact of
individuals with triatomid feces. The disease is under global
control, and the current frame shows a prevalence of 0.13%
in endemic areas, data obtained by serological survey [73].
da Silveira et al. [74] hypothesized that enteric glial cells
may be involved in the modulation of enteric inﬂammatory
responses or even control the colon’s dilation. Neuronal loss
is similar in dilated and nondilated portions of megacolon;
moreover, neuronal destruction present in megacolon is
preceded by glial component loss. The nondilated portion of
megacolon exhibited increased expression of glial ﬁbrillary
acidic protein comparable with the dilated portion and also
to the noninfected patients. These results suggest that glial
ﬁbrillaryacidicproteinentericglialcellspreventdilatationof
the organ and protect the enteric nervous system against the
inﬂammatory process and neuronal destruction, preventing
the destruction from expanding to unaﬀected areas of the
colon [75]. Subjects with megacolon had signiﬁcantly more
CD-57 natural killer cells and TIA-1 cytotoxic lymphocytes
within enteric ganglia, but numbers of CD-3 and CD-20
immunoreactive cells were not signiﬁcantly elevated. The
innervation of the muscle was substantially reduced to about
20% in megacolon, but asymptomatic seropositive subjects
were not diﬀerent of seronegative controls. Glial cell loss
occurredequallyinsymptomatic andunaﬀectedseropositive
subjects, although the proportion with glial ﬁbrillary acidic
proteinwasgreaterinseropositive,nonsymptomaticsubjects
[74].
Other molecular markers have been described in mega-
colon. For example, dilated portions of colon present with
high levels of substance P, a neurotransmitter involved in
pain transmission that causes rapid contractions of the
gastrointestinalsmoothmuscleandmodulatesinﬂammatory
and immune responses, and low levels of the NK1 receptor.
Conversely, nondilated colon and noninfected individuals
present low levels of substance P and high levels of NK1
receptor, which may indicate a neuroimmune relationship
occurring in Chagas disease [76].
It is believed that the presence of positive Foxp3 (a pro-
tein involved in immune system responses) cells [Foxp3(+)]
may help control the inﬂammatory process through the
management of lymphocyte migration. Chagas disease
patients without megacolon presented with an increased
concentration of Foxp3(+) cells in all colon layers compared
with megacolon patients and noninfected individuals. These
cells were situated mainly near the blood vessels and rarely
were associated with the inﬂammatory foci; consequently,
they seemed to prevent neuronal destruction and megacolon
development [77].
The expression of molecules responsible for activation
of T cells by neurons and enteric glial cells was investigated
and shows only enteric glial cells of Chagasic patients
with megacolon expressed HLA-DR complex class II and
costimulatory molecules [78]. Therefore, the development
of megacolon after acute infection with T. cruzi is associated
with a maintained invasion of enteric ganglia with cytotoxic
T cells and loss of muscle innervation. However, changes
in glial cell numbers are not associated with progression of
enteric neuropathy.
4.The BrazilianSurveyon ChagasDisease
The main results of three large national surveys on Cha-
gas disease (entomologic, seroprevalence and electrocardio-
graphic) carried out in Brazil from late 1970s to the early
1980s served as baseline for the deﬁnition of the control
measures adopted in the country [14]. The proportion of
infected people was much higher in areas where Triatoma
infestans, the most eﬃcient vector of Chagas disease among
the ﬁve principal species involved in transmission at that
time, was predominant. Similar result was observed in
places where Triatoma sordida was dispersed, mainly in the
country’s central region, which corresponds to its native
area. These ﬁndings are likely related to the colocalization
of the geographic distribution of both vectors, since T.
sordida is not considered an important player in Chagas
disease transmission. In the semiarid, endemic, Brazilian
Northeastern area, rates of human infection by Triatoma8 Journal of Tropical Medicine
brasiliensis and Triatoma pseudomaculata were much lower,
although both vectors may have some relevance in the
maintenance of the disease. As for areas with Panstrongylus
megistus, human infection varied according to the levels
of vector domiciliation. When Panstrongylus megistus is
resident this can demonstrate that it has an important
role in domestic transmission of T. cruzi, as in the humid
coast of the northeast. In some parts of the Bahia state,
Panstrongylusmegistusrepresentedtheexclusivevectorofthe
disease. Based upon the results of the seroprevalence survey,
an electrocardiographic study was carried out in 11 Brazilian
states, which showed marked diﬀerences in the presence of
cardiac alterations among diﬀerent geographical areas of the
country [14].
A survey for seroprevalence of Chagas disease was held
from 2001 to 2008 in a representative sample of Brazilian
children (up to 5 years old) living in rural areas of all
Brazilian states but Rio de Janeiro. Blood on ﬁlter paper
was collected from 104,954 children and screened in a single
laboratory with two serological tests: indirect immunoﬂuo-
rescence and enzyme-linked immunoassay. All samples with
positive or undetermined results, as well as 10% of all nega-
tive samples, were submitted to a quality control reference
laboratory, which performed both tests a second time, in
addition to the western blot assay of TESA (trypomastigote
excreted secreted antigen). All children with conﬁrmed
positive result (n = 104, prevalence = 0.1%) had a followup
visit and were submitted to a second blood collection, this
time a whole blood sample. In addition, blood samples
from the children’s mothers and relatives were collected. The
infectionwasconﬁrmedinonly32(0.03%)ofthosechildren.
From those, 20 (0.025%) had maternal positive results, sug-
gesting congenital transmission; 11 (0.01%) had noninfected
mothers, indicating a possible vectorial transmission; and
in a single child, whose mother had died, the transmission
mechanism could not be elucidated. In further 41 visited
children, the infection was conﬁrmed only in their mothers
suggesting passive transference of maternal antibodies; in
other 18, both child and mother were negative; and in 13
cases, the subjects were not localized. The 11 children that
acquired the infection presumably through the vector were
distributed mainly in the northeast region of Brazil (states of
Piau´ ı, Cear´ a, Rio Grande do Norte, Para´ ıba and Alagoas), in
additiontoonecaseinAmazonas(northregion)andanother
in Parana (south region) [79].
Remarkably,60%ofthe20probablycongenitaltransmis-
sion cases were from a single state, Rio Grande do Sul, with
the remaining cases distributed in numerous other states.
This is the ﬁrst report demonstrating regional geographical
diﬀerences in the vertical transmission of Chagas disease
in Brazil, and the hot spot in Rio Grande do Sul probably
reﬂects the predominant T. cruzi g r o u pI I da n dI I e( n o wT c V
and TcVI) found in this state. Overall, these results show
that the regular and systematic control programs against the
transmissionofChagasdisease,togetherwithsocioeconomic
changes observed in Brazil in the last decades, were eﬀective
in interrupting the vectorial transmission of Chagas disease
inthecountry.Furthermore,thesedatareinforcetheneedfor
maintenance of the control programs in order to consolidate
this major advance in public health [79, 80].
5. Conclusions
Chagas disease is still active in various countries of
Latin America and aﬀects a great number of individuals
who undergo undiagnosed until they manifest the typical
advanced symptoms or are aﬀected by other concomitant
pathologies. There has been signiﬁcant progress in under-
standing the biological and genetic diversity of the parasite,
as well as the population polymorphisms associated with
susceptibility to this disease. However, many other aspects
such as host-parasite interactions, genetic mechanisms of
cellular interaction, genetic variability, and tropism are not
enough known. Further investigations on these aspects are
necessary to clarify the T. cruzi’s mechanisms of action and
s u p p o r tr o b u s te ﬀorts on public health to eradicate the
disease.
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